Forgot your password?
Forgot your username?
JOIN THE LPMA
FIND A PSYCHIATRIST
FOR THE PUBLIC
News, Information & Links
Continuing Medical Education
LPMA News & Updates
APA News & Updates
SAVE THE DATE
Be sure to mark your calendars!
2016 Fall Meeting
Renaissance Arts Hotel in New Orleans
September 30 - October 01, 2016
More details coming soon!
Find a Psychiatrist
Resources for the Public
Calendar of Events
Spring Meeting Highlights
Mississippi Exec Angela Ladner with friends and members pausing for the peanut butter and jelly sandwiches and hot chocolate provided by the hotel each night! Yummy!!
Dr. Dean Robinson receives special thanks from the membership for two great years of service as President
Dr. Lee Stevens is given appreciation for his service as Past President
Dr. Lee Michals receives LSU Shreveport Excellence in Psychiatry Award for Graduating Residents-Fellows
Dr. Jill McCall is awarded the Resident-Fellow LSU New Orleans Excellence in Psychiatry Award
Dr. Veronique Haymon receives the Tulane Resident-Fellow Excellence in Psychiatry Award
Not pictured is Dr. Jason Boudreaux who received the Resident-Fellow LSU Baton Rouge Excellence in Psychiatry Award. Congratulations to all!
Psychiatric News Alert
The Voice of the
American Psychiatric Association
and the Psychiatric Community
Quetiapine Appears Effective as Monotherapy for PTSD, Study Shows
The atypical antipsychotic quetiapine appears to be effective as a single agent in the treatment of posttraumatic stress disorder (PTSD), according to a
AJP in Advance
Not all patients with PTSD respond to first-line antidepressant treatment, and current VA/Department of Defense guidelines recommend quetiapine and other antipsychotic medications as adjunctive treatments. Researchers from several VA centers and research institutions sought to determine the efficacy of quetiapine as monotherapy.
Eighty veterans meeting criteria for chronic PTSD were randomly assigned to treatment with either quetiapine or placebo tablets for 12 weeks. Quetiapine was initiated at a dose of 25 mg at bedtime and gradually titrated up to a minimum of 50 mg and maximum of 800 mg daily. The participants were evaluated at weeks 1, 2, 4, 8, and 12.
The primary outcome measure was the total Clinician-Administered PTSD Scale (CAPS) score. Secondary efficacy measures included the CAPS subscales, the Davidson Trauma Scale, the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions (CGI) scales for severity of illness and improvement, the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A).
Patients in the quetiapine group experienced greater reductions in CAPS total, re-experiencing, and hyperarousal scores than those in the placebo group. (Scores on the CAPS avoidance/numbing subscale and the PANSS negative symptom subscale did not differ from those of the placebo...
LPMA • 9655 Perkins Rd. #C-152 • Baton Rouge, LA 70810 • PH: 225-761-3718 • FAX: 228-215-1256 •
Web Design by
Bruner and Company